At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
In Brief
A Phase 1 clinical trial evaluating TTX-030, Pembrolizumab, and 2 other interventions for Solid Tumor and Lymphoma. Completed, enrolled 56 participants across 16 sites.
Detailed Summary
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies.
Study Details
Timeline
Interventions
Variable dose and schedule
Dose and schedule per standard of care
Dose and schedule per standard of care
Dose and schedule per standard of care